Several agents from a packed pipeline of anti-amyloid therapies for the treatment of Alzheimer’s disease may come to market within the next year, prompting experts in the field to ask: Are the systems of care within neurology and health care in general ready for the changes to dementia care delivery that will come with more widespread use of these medications?
What Health Care Systems Need to Do to Prepare for the Pipeline of New Alzheimer’s Drugs
View Content